Janet Grove
Director/Board Member at INMED PHARMACEUTICALS INC.
Net worth: - $ as of 2024-03-30
Profile
Janet P.
Grove is currently an Independent Director at InMed Pharmaceuticals, Inc. and a Director at Genome British Columbia and Phoenix Molecular Designs Ltd.
She previously worked as Vice President at QLT, Inc. and as a Partner at Norton Rose Fulbright Canada LLP.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-12-22 | 0 ( -.--% ) | - $ | 2024-03-30 |
Janet Grove active positions
Companies | Position | Start |
---|---|---|
INMED PHARMACEUTICALS INC. | Director/Board Member | 2022-02-10 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
Former positions of Janet Grove
Companies | Position | End |
---|---|---|
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright Canada LLP Miscellaneous Commercial ServicesCommercial Services Part of Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP provides legal services. The private company is based in Québec, Canada. | Corporate Officer/Principal | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
INMED PHARMACEUTICALS INC. | Health Technology |
Private companies | 4 |
---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Commercial Services |
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright Canada LLP Miscellaneous Commercial ServicesCommercial Services Part of Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP provides legal services. The private company is based in Québec, Canada. | Commercial Services |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | Commercial Services |
- Stock Market
- Insiders
- Janet Grove